The Benchmark Company slashes price target on BIOLASE Inc. [BIOL] – find out why.

BIOLASE Inc. [NASDAQ: BIOL] loss -3.07% on the last trading session, reaching $0.85 price per share at the time. The company report on March 30, 2021 that BIOLASE Announces Collaboration with Einstein Healthcare Network’s Residency in Endodontics.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Endodontic residents receive hands-on training with dental lasers to further education and foster easy integration into future dental practices.

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced a pilot program with Einstein Healthcare Network’s residency in endodontics to train endodontic residents in the use of Waterlase dental lasers. The goal of the program is to offer residents hands-on experience with dental lasers that are already in use across the industry, allowing residents to immediately implement their training when joining a future practice.

BIOLASE Inc. represents 149.38 million in outstanding shares, while the company has a total market value of $128.26 million with the latest information. BIOL stock price has been found in the range of $0.85 to $0.8988.

If compared to the average trading volume of 21.23M shares, BIOL reached a trading volume of 4244462 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about BIOLASE Inc. [BIOL]:

The Benchmark Company have made an estimate for BIOLASE Inc. shares, keeping their opinion on the stock as Speculative Buy, with their previous recommendation back on June 19, 2019. While these analysts kept the previous recommendation, Singular Research raised their target price to Buy. The new note on the price target was released on April 25, 2017, representing the official price target for BIOLASE Inc. stock. Previously, the target price had yet another drop from $4 to $2.50, while WallachBeth kept a Hold rating on BIOL stock. On November 12, 2013, analysts decreased their price target for BIOL shares from 3.50 to 2.75.

The Average True Range (ATR) for BIOLASE Inc. is set at 0.09, with the Price to Sales ratio for BIOL stock in the period of the last 12 months amounting to 5.63. The Price to Book ratio for the last quarter was 7.73, with the Price to Cash per share for the same quarter was set at 0.12.

Trading performance analysis for BIOL stock

BIOLASE Inc. [BIOL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.55. With this latest performance, BIOL shares dropped by -15.84% in over the last four-week period, additionally plugging by 180.90% over the last 6 months – not to mention a rise of 58.40% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BIOL stock in for the last two-week period is set at 45.37, with the RSI for the last a single of trading hit 44.36, and the three-weeks RSI is set at 46.71 for BIOLASE Inc. [BIOL]. The present Moving Average for the last 50 days of trading for this stock 0.9969, while it was recorded at 0.9305 for the last single week of trading, and 0.5615 for the last 200 days.

BIOLASE Inc. [BIOL]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and BIOLASE Inc. [BIOL] shares currently have an operating margin of -81.37 and a Gross Margin at +27.10. BIOLASE Inc.’s Net Margin is presently recorded at -73.88.

Return on Total Capital for BIOL is now -79.85, given the latest momentum, and Return on Invested Capital for the company is -104.10. Return on Equity for this stock declined to -234.22, with Return on Assets sitting at -45.61. When it comes to the capital structure of this company, BIOLASE Inc. [BIOL] has a Total Debt to Total Equity ratio set at 182.14. Additionally, BIOL Total Debt to Total Capital is recorded at 64.56, with Total Debt to Total Assets ending up at 44.52. Long-Term Debt to Equity for the company is recorded at 181.23, with the Long-Term Debt to Total Capital now at 63.48.

Reflecting on the efficiency of the workforce at the company, BIOLASE Inc. [BIOL] managed to generate an average of -$124,659 per employee. Receivables Turnover for the company is 3.85 with a Total Asset Turnover recorded at a value of 0.62.BIOLASE Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 3.10.

BIOLASE Inc. [BIOL]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, BIOLASE Inc. posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.17/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -11.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BIOL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BIOLASE Inc. go to 20.00%.

An analysis of insider ownership at BIOLASE Inc. [BIOL]

There are presently around $6 million, or 11.40% of BIOL stock, in the hands of institutional investors. The top three institutional holders of BIOL stocks are: ORACLE INVESTMENT MANAGEMENT INC with ownership of 1,739,100, which is approximately 0% of the company’s market cap and around 5.26% of the total institutional ownership; VANGUARD GROUP INC, holding 1,287,859 shares of the stock with an approximate value of $1.09 million in BIOL stocks shares; and PERKINS CAPITAL MANAGEMENT INC, currently with $1.03 million in BIOL stock with ownership of nearly 9.473% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in BIOLASE Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 21 institutional holders increased their position in BIOLASE Inc. [NASDAQ:BIOL] by around 2,939,185 shares. Additionally, 15 investors decreased positions by around 754,598 shares, while 9 investors held positions by with 3,709,932 shares. The mentioned changes placed institutional holdings at 7,403,715 shares, according to the latest SEC report filing. BIOL stock had 11 new institutional investments in for a total of 1,197,523 shares, while 10 institutional investors sold positions of 309,320 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam